Advertisement

Topics

Genentech’s Rituxan Hycela Receives FDA Approval for Treatment of Certain Blood Cancers

10:44 EDT 23 Jun 2017 | Speciality Pharma Journal

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved RITUXAN HYCELA™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated …

Original Article: Genentech’s Rituxan Hycela Receives FDA Approval for Treatment of Certain Blood Cancers

NEXT ARTICLE

More From BioPortfolio on "Genentech’s Rituxan Hycela Receives FDA Approval for Treatment of Certain Blood Cancers"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...